NUVB Stock Price, Nuvation Bio Inc. Quote, Chart

Market Summary

USD2.57-0.03

Delayedas of 22 Apr 2024, 01:05 pm

-1.15%

NUVB Stock Price

View Fullscreen

NUVB RSI Chart

NUVB Valuation

Market Cap

569.5M

Price/Earnings (Trailing)

-7.51

Price/Sales (Trailing)

23.14

EV/EBITDA

-6.97

Price/Free Cashflow

-8.38

NUVB Price/Sales (Trailing)

NUVB Profitability

EBT Margin

-308.00%

Return on Equity

-12.53%

Return on Assets

-12.2%

Free Cashflow Yield

-11.94%

NUVB Fundamentals

NUVB Revenue

Revenue (TTM)

24.6M

Rev. Growth (Yr)

99.38%

Rev. Growth (Qtr)

7.67%

NUVB Earnings

Earnings (TTM)

-75.8M

Earnings Growth (Yr)

33.86%

Earnings Growth (Qtr)

29.83%

Breaking Down NUVB Revenue

52 Week Range

1.182.63

(Low)(High)

Last 7 days

-13.1%

Last 30 days

34.4%

Last 90 days

76.7%

Trailing 12 Months

50.9%

How does NUVB drawdown profile look like?

NUVB Financial Health

Current Ratio

44.11

NUVB Investor Care

Shares Dilution (1Y)

0.19%

Diluted EPS (TTM)

-0.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	11.5M	16.7M	21.1M	24.6M
2022	3.5M	3.5M	4.8M	7.4M
2021	1.9M	2.1M	2.5M	3.0M
2020	1.5M	1.6M	1.8M	1.9M
2019	0	0	0	1.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Nuvation Bio Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 09, 2024	wang junyuan jerry	acquired	-	-	1,378,990	ceo, anheart therapeutics ltd.
Apr 09, 2024	wang junyuan jerry	acquired	-	-	550,758	ceo, anheart therapeutics ltd.
Apr 09, 2024	cui xiangmin	acquired	-	-	4,183,000	-
Apr 09, 2024	cui xiangmin	acquired	-	-	314,106	-
Apr 09, 2024	cui xiangmin	acquired	-	-	1,675,240	-
Sep 21, 2023	nodelman oleg	bought	72,138	1.3611	53,000	-
Sep 20, 2023	nodelman oleg	bought	159,490	1.362	117,100	-
Sep 19, 2023	nodelman oleg	bought	6,460,640	1.2562	5,143,000	-
Feb 21, 2023	nodelman oleg	bought	72,138	1.3611	53,000	-
Feb 20, 2023	nodelman oleg	bought	159,490	1.362	117,100	-

Which funds bought or sold NUVB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	EDBI Pte Ltd	unchanged	-	2,706,170	4,624,640	5.20%
Apr 15, 2024	Pallas Capital Advisors LLC	added	15.69	27,011	42,111	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	20.64	310,746	473,589	0.01%
Apr 15, 2024	Palumbo Wealth Management LLC	new	-	73,052	73,052	0.03%
Apr 11, 2024	Fortitude Family Office, LLC	unchanged	-	812	1,387	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	0.94	1,290	10,670	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.25	1,268,220	11,045,100	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	284	1,845,380	2,398,210	-%
Feb 29, 2024	Tortoise Investment Management, LLC	unchanged	-	2,338	20,766	-%

Are Funds Buying or Selling NUVB?

Are funds buying NUVB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NUVB

No. of Funds

Unveiling Nuvation Bio Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 26, 2024	hung david	27.7%	61,269,498	SC 13D/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 29, 2024	blackrock inc.	5.9%	12,882,429	SC 13G
Feb 14, 2023	deep track capital, lp	3.76%	8,221,188	SC 13G/A
Feb 13, 2023	blackrock inc.	5.0%	10,996,735	SC 13G
Feb 13, 2023	omega fund v, l.p.	6.9%	15,072,340	SC 13D/A
Feb 09, 2023	vanguard group inc	4.55%	9,932,441	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Jun 23, 2022	deep track capital, lp	5.26%	11,471,281	SC 13G
Feb 11, 2022	castle creek arbitrage, llc	10%	215,426	SC 13G/A

Recent SEC filings of Nuvation Bio Inc.

View All Filings

Date Filed	Form Type	Document
Apr 18, 2024	S-8	Employee Benefits Plan
Apr 11, 2024	3	Insider Trading
Apr 11, 2024	3	Insider Trading
Apr 11, 2024	4	Insider Trading
Apr 11, 2024	4	Insider Trading
Apr 11, 2024	4	Insider Trading
Apr 10, 2024	8-K	Current Report
Apr 02, 2024	3	Insider Trading
Mar 26, 2024	SC 13D/A	13D - Major Acquisition
Mar 25, 2024	8-K	Current Report

Peers (Alternatives to Nuvation Bio Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Nuvation Bio Inc. News

Latest updates

Nuvation Bio Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	7.7%	7,023,000	6,523,000	6,086,000	4,979,000	3,522,500	2,127,000	841,000	958,000	902,000	847,000	776,000	438,000	459,000	445,000	522,000	519,000	-
Operating Expenses	-20.9%	20,831,000	26,339,000	26,131,000	26,521,000	24,334,500	29,338,000	37,870,000	28,192,000	29,609,000	22,791,000	20,434,000	20,484,000	13,768,000	11,546,000	9,017,000	9,220,000	-
S&GA Expenses	-29.5%	5,480,000	7,778,000	7,541,000	7,734,000	7,464,000	8,044,000	8,948,000	7,463,000	7,607,000	5,669,000	6,400,000	4,605,000	4,432,000	2,919,000	1,672,000	1,925,000	-
R&D Expenses	-17.3%	15,351,000	18,561,000	18,590,000	18,787,000	16,870,500	21,294,000	28,922,000	20,729,000	22,002,000	17,122,000	14,034,000	15,879,000	9,336,000	8,627,000	7,345,000	7,295,000	-
EBITDA Margin	21.5%	-3.07	-3.91	-5.40	-9.10	-13.96	-22.43	-29.05	-25.13	-29.25	-29.69	-30.18	-28.54	-21.37	-18.84	-20.75	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	29.8%	-13,787,000	-19,649,000	-20,640,000	-21,726,000	-20,845,000	-27,203,000	-34,858,000	-21,293,000	-25,134,000	-21,979,000	-19,333,000	-20,402,000	-13,280,000	-11,034,000	-8,599,000	-8,746,000	-
EBT Margin	21.5%	-3.08	-3.93	-5.41	-9.12	-13.99	-22.47	-29.10	-25.19	-29.31	-29.76	-30.24	-28.60	-21.42	-18.84	-20.76	-	-
Net Income	29.8%	-13,787,000	-19,649,000	-20,640,000	-21,726,000	-20,845,000	-27,203,000	-34,858,000	-21,293,000	-25,134,000	-21,979,000	-19,333,000	-20,402,000	-7,299,008	-11,034,000	-8,599,000	-8,746,000	-
Net Income Margin	21.5%	-3.08	-3.93	-5.41	-9.12	-13.99	-22.47	-29.10	-25.19	-29.31	-27.39	-27.42	-25.39	-21.42	-18.84	-20.76	-	-
Free Cashflow	7.1%	-15,030,000	-16,170,000	-17,584,000	-19,444,000	-16,275,000	-28,206,000	-27,032,000	-25,043,000	-23,596,000	-13,262,000	-16,944,000	-14,844,000	-13,034,000	-8,135,000	-6,933,000	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q2	2019Q4
Assets	-1.5%	621	631	641	657	672	686	720	752	776	798	814	832	222	145	146	133	121
Current Assets	-1.4%	616	625	637	653	667	681	714	748	772	797	813	831	221	2.00	2.00	-	120
Cash Equivalents	74.8%	43.00	24.00	50.00	30.00	101	139	102	106	132	345	450	639	30.00	8.00	9.00	-	3.00
Net PPE	-6.2%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	1.00
Liabilities	-15.1%	16.00	19.00	17.00	16.00	17.00	19.00	27.00	28.00	30.00	28.00	25.00	26.00	7.00	1.00	0.00	2.00	3.00
Current Liabilities	-13.4%	14.00	16.00	13.00	13.00	13.00	14.00	21.00	21.00	17.00	13.00	10.00	10.00	7.00	-	0.00	-	3.00
Shareholder's Equity	-1.1%	605	612	625	641	655	668	693	724	746	769	789	806	215	92.00	103	0.00	118
Retained Earnings	-4.2%	-342	-329	-309	-288	-267	-246	-219	-184	-162	138	116	-96.36	-75.95	-10.92	-4.18	0.00	-34.30
Additional Paid-In Capital	-	-	-	-	-	-	-	-	-	-	-	-	-	23.00	16.00	0.00	0.00	-
Shares Outstanding	0.0%	219	219	219	219	219	218	218	218	218	218	218	218	149	-	-	-	400
Float	-	-	-	261,250	-	-	-	468,976	-	-	-	1,340	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	7.1%	-15,030	-16,170	-17,500	-19,300	-16,169	-28,092	-26,918	-24,929	-23,482	-13,148	-16,830	-14,730	-12,937	-8,038	-6,836	-8,718	-
Share Based Compensation	-31.5%	3,722	5,431	5,523	4,837	4,988	2,940	4,787	3,577	2,800	2,749	2,153	1,566	1,125	348	389	340	-
Cashflow From Investing	445.7%	33,163	-9,592	37,346	-51,996	-21,829	106,369	-15,532	-5,551	-189,264	-91,722	-172,598	-1,085	-	6,517	10,820	10,608	-
Cashflow From Financing	55.8%	120	77.00	133	298	407	258	-3,602	4,264	538	-32.00	57.00	624,964	66,295	73,040	3.00	-	-

NUVB Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 71,289	$ 87,815
General and administrative	28,533	31,919
Total operating expenses	99,822	119,734
Loss from operations	(99,822)	(119,734)
Other income (expense):
Interest income	24,611	7,448
Investment advisory fees	(949)	(872)
Change in fair value of warrants liability	497	10,187
Realized loss on marketable securities	(139)	(1,228)
Total other income (expense), net	24,020	15,535
Loss before income taxes	(75,802)	(104,199)
Provision for income taxes	0	0
Net loss	$ (75,802)	$ (104,199)
Net loss per share attributable to common stockholders, basic	$ (0.35)	$ (0.48)
Net loss per share attributable to common stockholders, diluted	$ (0.35)	$ (0.48)
Weighted average common shares outstanding, basic	218,880	216,721
Weighted average common shares outstanding, diluted	218,880	216,721
Comprehensive loss:
Net Income (Loss)	$ (75,802)	$ (104,199)
Other comprehensive loss, net of taxes:
Change in unrealized gain (loss) on available-for-sale securities, net	5,707	(4,341)
Comprehensive loss	$ (70,095)	$ (108,540)

NUVB Balance Sheet

2023-12-31

Consolidated Balance Sheet - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 42,649	$ 101,099
Prepaid expenses and other current assets	1,519	3,819
Marketable securities	568,564	559,915
Interest receivable on marketable securities	3,702	2,485
Total Current Assets	616,434	667,318
Property and equipment, net	717	894
Lease security deposit	141	138
Operating lease right-of-use assets	3,605	3,791
Other non-current assets	587	0
Total Assets	621,484	672,141
Current liabilities
Accounts payable	2,209	2,139
Current operating lease liabilities	1,972	1,206
Accrued expenses	9,793	9,816
Total Current Liabilities	13,974	13,161
Warrant Liability	353	850
Non-current operating lease liabilities	2,035	3,054
Total Liabilities	16,362	17,065
Commitments and contingencies
Stockholders' Equity
Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000 (Class A 1,000,000,000,Class B 60,000,000) shares authorized as of December 31, 2023 and December 31, 2022, respectively, 219,046,219 (Class A 218,046,219, Class B 1,000,000) and 218,632,699 (Class A 217,632,699, Class B 1,000,000) shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	947,745	927,604
Accumulated deficit	(342,804)	(267,002)
Accumulated other comprehensive (loss) income	181	(5,526)
Total Stockholders' Equity	605,122	655,076
Total Liabilities and Stockholders' Equity	$ 621,484	$ 672,141

About Nuvation Bio Inc.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

CEO	Dr. David T. Hung M.D.
WEBSITE	nuvationbio.com
INDUSTRY	Biotechnology
EMPLOYEES	54

Nuvation Bio Inc. Frequently Asked Questions

What is the ticker symbol for Nuvation Bio Inc.? What does NUVB stand for in stocks?

NUVB is the stock ticker symbol of Nuvation Bio Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nuvation Bio Inc. (NUVB)?

As of Fri Apr 19 2024, market cap of Nuvation Bio Inc. is 569.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NUVB stock?

You can check NUVB's fair value in chart for subscribers.

What is the fair value of NUVB stock?

You can check NUVB's fair value in chart for subscribers. The fair value of Nuvation Bio Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nuvation Bio Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NUVB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nuvation Bio Inc. a good stock to buy?

The fair value guage provides a quick view whether NUVB is over valued or under valued. Whether Nuvation Bio Inc. is cheap or expensive depends on the assumptions which impact Nuvation Bio Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NUVB.

What is Nuvation Bio Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, NUVB's PE ratio (Price to Earnings) is -7.51 and Price to Sales (PS) ratio is 23.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NUVB PE ratio will change depending on the future growth rate expectations of investors.